European Rare Diseases Partnership

Strategic Research & Innovation Agenda

Dissemination level: public consultation
Table of Contents

Vision of the European Rare Diseases Partnership ........................................4

1.1. Missions .............................................................................................................4

1.2. Building on Lessons learned .........................................................................4

1.3. intervention logic - Partnership Specific Impact Pathway (PSIP) ..................6

1.4. General Objectives ..........................................................................................7

1.4.1. GENERAL OBJECTIVE 1: DIAGNOSIS ESTABLISHED OR ENROLLMENT IN SYSTEMATIC
RESEARCH IN AVERAGE WITHIN 6 MONTHS AFTER COMING TO MEDICAL ATTENTION 7

1.4.2. GENERAL OBJECTIVE 2: 1000 NEW THERAPIES FOR RARE DISEASES APPROVED ..........7

1.4.3. GENERAL OBJECTIVE 3: BETTER UNDERSTANDING OF THE IMPACT OF RD ON PATIENTS,
FAMILIES AND SOCIETY .................................................................................8

1.5. Activities and resources (Operational Objectives) .........................................8

1.6. Synergies with other initiatives ....................................................................10

2. Specific Objectives of the European Rare Diseases Partnership ...............11

2.1. Specific Objective 1: Generation of knowledge and its translation into
medical and holistic intervention .......................................................................11

2.1.1. Challenge ..................................................................................................11

2.1.2. Scope .........................................................................................................12

2.1.3. Potential Outputs .......................................................................................13

2.1.4. Specific Outcomes ....................................................................................14

2.2. Specific Objective 2: Healthcare and research data are accessible, and
used, for scientific and regulatory evaluation and healthcare delivery ............14

2.2.1. Challenge ..................................................................................................14

2.2.2. Scope .........................................................................................................14

2.2.3. Potential Outputs .......................................................................................15

2.2.4. Specific Outcomes ....................................................................................16

2.3. Specific Objective 3: All activities empower, as equal partners, people living
with rare disease .................................................................................................16

2.3.1. Challenge ..................................................................................................16

2.3.2. Scope .........................................................................................................17

2.3.3. Potential Outputs .......................................................................................18

2.3.4. Specific Outcomes ....................................................................................18

2.4. Specific Objective 4: Increased capacity and skills of RD stakeholders to
optimise research to healthcare continuum .......................................................19

2.4.1. Challenge ..................................................................................................19

2.4.2. Scope .........................................................................................................19

2.4.3. Potential Outputs .......................................................................................19

2.4.4. Specific Outcomes ....................................................................................20
2.5. Specific Objective 5: Integrated multinational and multi-stakeholder Research & Innovation ecosystem for RD ................................................................. 20
   2.5.1. Challenge ................................................................................................. 20
   2.5.2. Scope ....................................................................................................... 21
   2.5.3. Potential Outputs .................................................................................... 21
   2.5.4. Specific Outcomes ................................................................................. 22

3. Performance Indicators .................................................................................... 22
4. Conclusions ....................................................................................................... 25
5. Annexes ........................................................................................................... 26
   5.1. Annex 1 - European Partnerships, EU Missions, EU Programmes, Projects and Organisations of potential relevance ......................................................... 26
   5.2. List of abbreviations .................................................................................... 37
Vision of the European Rare Diseases Partnership

1.1. Missions

The European Rare Diseases (RD) Partnership will be organised around the following ambition, vision, and mission.

**AMBITION:**

The European RD Partnership has the ambition to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in RD research and innovation, to support concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment. It will support the EU commitment to UN 2030 Agenda’s Sustainable Development Goals: (i) Good health & wellbeing (SDG3), (ii) industries, innovation and infrastructure (SDG9), and (iii) Reduced inequalities (SDG10) as well as the EU political priorities (a Europe fit for the digital age, an economy that works for people, a stronger Europe in the world, Promoting our European way of life and democracy).

**VISION:**

To leave no one behind, the European RD Partnership will deliver a RD multi-stakeholder ecosystem by supporting robust patient need-led research, developing new treatments and diagnostic pathways, by using the power of health and research data and spearheading the digital transformational change in RD research and innovation (R&I).

Finally, the Partnership will structure the European Research Area on RD by supporting the coordination and alignment of national and regional research strategies, including the establishment of public-private collaborations, through research activities all along the R&I value chain, ensuring that the journey from knowledge to patient impact is expedited, thereby optimizing EU innovation potential in RD.

This vision will be enabled by a tripartite mission to be accomplished by the end of the Partnership.

**MISSION:**

- Bring and share supporting R&I knowledge, resources and services from across Europe under one roof so that every RD research project would benefit from cross-disciplinary expertise, goal-oriented study planning and efficient execution.

- Enable every consenting patient living with a rare disease to be findable and enrolled in a suitable clinical study, by boosting generation and sharing of FAIR-compliant, regulatory-quality data from diversity of sources, with the ultimate goal to fasten advances in prevention, diagnosis, disease knowledge and treatment.

- Make Europe a global leader on rare disease research through a significant increase in investment to spur innovation, by aligning the regional, national and European research and innovation priorities, leading to job creation and improving EU competitiveness in R&I.

1.2. Building on Lessons learned

The European RD Partnership stems from joint actions between the EU Members States, Associated countries, European Commission and other relevant stakeholders. It builds on lessons learned from the European Joint Programme on Rare Diseases, EJP RD, a major milestone that was achieved in Europe to structure the RD research landscape. EJP RD was launched in 2019, as a prime example of Member States and other stakeholders working together on a more integrative and cross-sectorial approach to tackle health challenges. It gathered more than 130 institutions from 35 countries and built the foundations of RD ecosystem by integrating multinational RD funding, support services and data infrastructure (virtual platform of distributed FAIR data sources and services). The Partnership will benefit equally from the outputs but the ones that are key for the RDP of several other key programmes and initiatives supported by the EU (to only name few) as the European Reference Networks (ERN), their registries and their clinical research coordination platform ERICA; IMI projects like Connect for Children (C4C) pan-European collaborative paediatric...
network for high quality clinical trials in children, and Screen4Care; Orphanet, the EU-funded multilingual knowledge base on rare diseases and orphan drugs including ORPHA codes ontology; EU-funded research projects such as Solve-RD, accelerating RD diagnosis pathway for unsolved rare diseases for which the molecular underlying cause is not yet known; RD-Connect, a European genome-phenome analysis platform including directory of RD biobanks and samples; the European Rare Diseases Registry Infrastructure implemented by JRC, projects such as X-eHealth and EHDEN that target millions of health data records, and the 1+Million Genomes initiative targeting 1 million sequenced genomes accessible in the EU including RDs as key use case.

Finally, the national contributions will be essential to the European RD Partnership to ensure long-term commitment, integration of resources and best alignment of the national plans and/or national strategies to tackle rare diseases.

The RDP will consolidate and extend the achievements of EJP RD so that other actors can contribute more easily and efficiently to the generation of evidence that leads to concrete benefits for patients.

The ambition of the European RD Partnership will build on, contribute to and accelerate directly the goals set by the International Rare Diseases Research Consortium1 (IRDiRC). This is reflected in the General Objectives of the Partnership. The programme aims to provide solutions for tackling the identified main R&I bottlenecks that hinder the efficient development of better diagnosis, therapy and care fostered by research in the RD field which are: 1/ the need for further collaboration & alignment of research funding and optimal integration with national rare diseases plans/strategies; 2/ the huge gap in translation of research results to deliver cost-effective solutions for people living with a rare diseases (noting that the conduct of clinical studies is a burden that can be addressed); and 3/ the fragmentation of knowledge and data, lack of holistic R&I ecosystem. Research & Innovation activities on rare diseases should create value for patients by reducing suffering of people living with rare diseases through better prevention, better diagnosis and better treatment as a direct result of research outcomes. The European RD Partnership should drive the research cost effective translation and bringing innovation to address the unmet medical needs of the rare diseases community, while coordinating national research efforts and establishing a holistic research and innovation ecosystem of knowledge, data, disciplines, people and sectors.

1 IRDiRC goals for the decade 2017-2027 are: Goal 1 – All patients coming to medical attention with a suspected rare disease will be diagnosed within one year if their disorder is known in the medical literature; all currently undiagnosable individuals will enter a globally coordinated diagnostic and research pipeline; Goal 2 – 1000 new therapies for rare diseases will be approved, the majority of which will focus on diseases without approved options: Goal 3 – Methodologies will be developed to assess the impact of diagnoses and therapies on rare disease patients (Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective. C.P. Austin et al. Clin Transl Sci. 2018 Jan;11(1):21-27. doi: 10.1111/cts.12500. Epub 2017 Oct 23)
1.3. intervention logic - Partnership Specific Impact Pathway (PSIP)

VISION: To improve the health and well-being of 30 million persons living with a rare disease in Europe, by making Europe a world leader in RD research and innovation, and delivering concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment.
1.4. General Objectives

The General Objectives (GOs) of the European Rare Diseases Partnership are defined in line with the Partnership’s vision and mission to improve the health and well-being of people affected by rare diseases by delivering concrete health benefits through prevention, diagnosis and treatment development. It was agreed that they should be inspired by and fully aligned with the goals of IRDiRC. Moreover, they are contributing to EU political priorities (cf. “Ambition”) and to the Sustainable Development Goals (SDGs) of the 2030 Agenda for Sustainable Development adopted by the United Nations in 2015. In particular, they are affiliated with SDG3 “Ensure healthy lives and promote well-being for all at all ages”, SD9 “Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation”, and SDG10 “Reduce inequality within and among countries”.

1.4.1. General Objective 1: Diagnosis Established or Enrollment in Systematic Research in Average Within 6 Months After Coming to Medical Attention

Patients with undiagnosed diseases and their families often face an uncertain and unpredictable journey, called a diagnostic odyssey, which is particularly complex in the case of rare diseases as 50% of patients still do not have a final diagnosis, and when they do, it is on average after 4 years of the diagnostic journey.

The European RD Partnership will contribute to shortening the diagnostic pathway for patients with rare diseases. For those disorders already identified in the literature the ambition is that a patient is diagnosed within a maximum of six-months after the first medical appointment with a specialist. For the undiagnosed disorders efforts will be made to build and/or strengthen the bridge between research and healthcare to provide to every undiagnosed patient the possibility to be included in a globally coordinated diagnostic and research pipeline.

1.4.2. General Objective 2: 1000 New Therapies for Rare Diseases Approved

95% of RDs are still underserved in terms of research and patients with rare diseases, although diagnosed, face a lack of viable long-term treatment options. To contribute to IRDiRC goals, and more specifically Goal 2 – “1000 new therapies for rare diseases will be approved, the majority of which will focus on diseases without approved options”, the European RD Partnership, will accelerate the development of new therapies (especially for diseases without approved options) by providing the necessary support to research projects aimed at developing new treatments and by expediting clinical trial readiness of rare diseases, including contribution to regulatory fitness to enable regulatory approval.

---

2 General Objectives correspond to the impact aimed to be achieved by the European Rare Diseases Partnership, i.e., the wider & long term effects on society (including the environment), the economy and science, enabled by the outcomes of R&I actions.
1.4.3. **GENERAL OBJECTIVE 3: BETTER UNDERSTANDING OF THE IMPACT OF RD ON PATIENTS, FAMILIES AND SOCIETY**

Rare diseases place a significant burden on patients and their families, on caregivers and on society in general. For 52% of them, rare diseases mean a serious impact on their daily lives. Understanding of the impact of RDs on people lives means also better evaluation of the societal and healthcare costs and capacity to implement more inclusive, holistic healthcare approaches. Through required means (funding, data collection) and processes (involvement of people living with rare diseases at all levels) the Partnership will contribute to capturing of RD impact and comprehensive understanding of patients and carers needs leading to, in the long term, improved and/or new processes that will facilitate the diagnosis and care pathways and translate into meaningful societal support.

1.5. **Activities and resources (Operational Objectives)**

**Operational Objective 1: Investment in patient need-led research and innovation**

The European RD Partnership will implement annually competitive Joint Transnational Calls (JTC) to fund patient-needs driven, multinational, research projects, including the funding of dedicated support to patients’ organisations. Specific measures will be applied for the JTCs in order to improve the participation and visibility of under-represented countries in the European RD Partnership.

Other funding schemes will be used including support to expanding or establishing new networks for knowledge sharing targeting underserved Rare Diseases, and fund in-house research, through the Clinical Research Network (CRN). These latter funding schemes will be supported by direct use of EC funds, complemented by in-kind contributions of involved research performing organisations and possible in-cash and/or in-kind contributions of industry. Clinical trials conduct could benefit from these funding schemes; the resources expected for their implementation will need to be estimated.

**Operational Objective 2: Support robust data, resources and expertise infrastructure**

The state-of-the-art infrastructure, services and support will be further advanced so that clinical and translational RD research are highly productive.

The infrastructure of the clinical research network will be established by leveraging on and expanding and connecting existing resources and tools (e.g., EU RD Platform, EJP RD Virtual Platform, European patients’ registries and biobanks, as well as other national data sources & capacities). This infrastructure will comprise dedicated support services that will include, but are not limited to, provision of distributed and cloud computing and data exploitation facilities, innovative analysis resources, quality assurance services, research guidance on coordinated diagnostic, Patient-Centred Outcome Measures, biostatistical and multinational Clinical Trials. Other ad-hoc

---

3 Operational Objectives correspond to the actions, activities and resources that will be deployed by the European RD Partnership to achieve its Specific and General Objectives.

4 The Clinical Research Network has for objective to promote efficient implementation of clinical studies and preparedness for clinical trials. It connects various resources from the European RD Partnership partners and collaborators, supported by an IT infrastructure. It conducts internal research projects that are selected through internal calls and are backed by dedicated services, including but not limited to diagnostic research support, biostatistical guidance, clinical trials methodologies and operations, and Clinical Outcome Assessment support. Its IT infrastructure utilizes existing resources and platforms and extends them to allow for data exploitation for in-house research projects and piloting of the CRN.
support services (e.g., for identification of biomarkers and surrogate endpoints and validation, mHealth expertise) can be developed according to the emerging needs of the CRN. Importantly, these integrative services will be expanded, developed and deployed to support all activities of the European RD Partnership (beyond CRN). They will comprise data integration and coordination services and expanded mentoring services to support all funded projects. Ethics, Legal, Regulatory and Societal Impact support will also be implemented.

Operational Objective 3: Coordination and alignment of European, (inter)national and regional research strategies and resources

A fully integrated strategy and coordination will support effective public, public-private and civil society partnerships. National coordination and alignment will be ensured through maximisation of the national in-kind contributions in advance and all along the lifetime of the Partnership. The National Mirror Groups (NMGs) will be set-up and supported to organise coordinated interaction between the Partnership and national and regional stakeholders. They will catalyse the transfer of good practices to the national and regional level, including leveraging the power of national/European data sources, by making nationwide or regional RD discoverable and actionable for international RD research.

The cooperation with international partners will be ensured through (1) the operation of the IRDiRC Scientific Secretariat to provide strong links to international collaborators (such as the US National Institutes of Health) as well as a joint management of research and innovation strategy; (2) the maintenance of already established collaboration with Associated partners (like Canada, Israel and Australia) contributing to and aligning with research and training activities; (3) expanding the collaboration and integration of other countries willing to join with their knowledge and resources; and (4) Stimulating and supporting the development of trans-regional activities.

Operational Objective 4: Training and education (of RD stakeholders)

The Capacity building of all stakeholders will support new generations of researchers, clinicians, patient representatives and policy makers, decrease knowledge and competences gaps between countries, empower patients and constantly improve the capacities of the experienced RD stakeholders.

The European RD Partnership will integrate training and capacity building components as part of its support activities for funded research projects and Clinical Research Network. Dedicated efforts will be made to train patients and their representatives on topics of relevance to ensure and accelerate their informed engagement at all levels. To support access to RD education for overall society and stakeholders, comprising general student and clinician population interested in RDS, including at national level, the Partnership will take advantage of already initiated by EJP RD massive open online courses and expand them to accredited education programmes.

Operational Objective 5: Multi-stakeholder collaboration

All types of actors will be involved, along the health and research value chain, in priority setting. These include research funders; research and innovation communities across life science and technology/data disciplines; users represented by patients and citizens, health care professionals and health care providers; as well as EU-wide and national policy makers, regulatory authorities, Health Technology Assessment bodies, and health care payers. The European RD Partnership will gradually bring on board additional stakeholders. Mechanisms will be created to onboard Under-represented,
including EU13® countries, Associated and non-EU countries. The possible inclusion of industry as full beneficiaries in the partnership is considered as major gamechanger in building integrative RD ecosystem and advancing European RD Partnership goals. This inclusion needs to happen in full synergy with some other initiatives listed in annex 1.

The multistakeholder collaboration, that is at the root of the partnership, requires an effective governance framework. The Terms of Reference and guidance for the governance of the partnerships under Horizon Europe, that will be provided by the EC, and learnings from other initiatives such as EJP RD, will be used to set the organisational and governance structure of the consortium that will comprise decision-making bodies; executive bodies and advisory bodies. A central coordination and management of the consortium will take advantage of experience and tools already acquired through EJP RD to establish active and proficient coordination office that will accompany European RD Partnership partners by providing operational and strategic support. This will include the management of the monitoring of partnership operational, specific and general objectives through adapted monitoring system in line with the requirements of Horizon Europe.

The detailed breakdown of resources to specific activities will be decided by the RD partnership decision-making bodies when adopting annual work programmes, considering advice from the constituted advisory bodies. The description of specific activities and allocated resources will be provided in annual activity reports. The annual activity reports will also report on the Key Performance Indicators used to monitor progress towards reaching the European RD Partnership objectives, with specific baselines and targets.

### 1.6. Synergies with other initiatives

To reach its ambition, the European RD Partnership will leverage relevant complementary activities in Europe and will conversely generate content that may benefit other EU initiatives.

Collaborations are envisioned with (i) Horizon Europe European Partnerships, (ii) European Union programmes, projects and initiatives, (iii) large European or international initiatives, should they be public, public-private or private including no-profit.

Synergies will be sought with the aim to support and enhance specific RDP actions (including possible co-funding, parallel funding or subsequent funding), as well as to ensure relevant dissemination and exploitation of results from the European RD Partnership. For instance, regional funds can support the uptake of evidence-based results from e.g., the funded research projects, the services-innovations and other innovations identified through the European RD partnership.

For each collaboration opportunity, “opportunity topics” cover diagnosis, treatment, care, research, data and infrastructures that set out the roadmap for the next decade of rare disease policies.

Key collaboration opportunities have been identified with several EU Partnerships implemented in the Horizon Europe context in three main areas: (i) the Health Cluster (ii) the Digital, Industry and Space Cluster; (iii) partnerships with cross-sectoral themes.

A close collaboration will be initiated with other European Health Partnerships, starting

---

5 List of EU13 countries: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, Slovenia
with: (1) the Innovative Health Initiative (IHI), (2) the ERA4Health - Fostering a European Research Area for Health Research, as well as (3) the European Partnership on Personalised Medicine and (4) the Partnership Transforming Health and Care Systems (THCS). Aside from the Health cluster, collaboration is also foreseen with cross-sectoral Partnerships such as the EIT Health, Innovative SMEs and European Open Science Cloud (EOSC). Finally, to ensure the best uptake and alignment in data, computing and machine-learning research areas, two Partnerships lying under the Digital, Industry and Space Cluster have been identified as potential candidate for partnerships, one on High Performance Computing (EuroHPC) and one on Artificial Intelligence, data and robotics. These initiatives, and others with potential for collaboration, are listed in annex 1.

The European RD Partnership will also take advantage of pre-existing and to-be funded EU Programmes and EU projects to maximise the use of resources and alignment. The European RD Partnership will namely build synergies with Horizon Europe initiatives, such as the European Innovation Council (EIC), the Marie Skłodowska-Curie Actions (MSCA); and Missions, in particular the Cancer Mission. The Partnership will also develop specific synergies with the EU4Health and the Digital Europe Programmes. Other EU support schemes such as the European Social Fund Plus (ESF+), the invest in education, employment and social inclusion (InvestEU) and the European Regional Development Fund (ERDF) will also systematically be considered to develop the best uptake and development of the European RD Partnership activities. Several EU programmes and projects have been pre-identified for potential collaboration (see annex 1).

In addition to EU-funded partnerships and programmes, collaboration will also be developed with overarching European or international major initiatives such as the Rare Disease Moonshot launched in December 2022 or the Together4Rare initiative. Collaboration with non-for-profit organisations and charities who are paving the way in RD research collaboration will also be sought.

2. Specific Objectives\(^6\) of the European Rare Diseases Partnership

2.1. Specific Objective 1: Generation of knowledge and its translation into medical and holistic intervention

2.1.1. Challenge

The journey from bench to bedside should be accelerated thanks to the generation of knowledge and its translation into medical and holistic intervention, but still faces the following challenges:

**Insufficient support of RD research**

More than 90% of RDs are not properly addressed in terms of research and accompanying sustainable R\&I funding. From the scientific perspective this includes lack of knowledge of the underlying molecular disease cause, pathophysiology, lack of disease models and potential therapeutic targets within a disease/ disease group hampering diagnosis and development of suitable treatment options. From the

\(^6\) Specific Objectives correspond to the outputs (direct results of the project) and outcomes (short/medium term effect of the projects results) that the European Rare Diseases Partnership aims to achieve.
funding perspective, the high risk-to-investment return ratios for private companies
discourages their engagement in RD therapeutic development, and concomitant
lack of alternative R&I pathways to the patient slows down the journey from the bench
to bedside. A streamlined and optimized, jointly driven public-private pipeline is
needed, supported by powerful data management.

**Need for more innovative RD research models**

One disease - one treatment equation is not a viable option for 7000 rare diseases.
Standard research in common disease conditions explores cell, tissue and animal work
in individual disease states in comparison with health, to identify disease pathways and
potential therapeutic targets. In RDs very small numbers of patients affected with
individual rare diseases make the use of such standard clinical development
pathways often impracticable. Specific approaches and linked research
infrastructure are not currently in place to explore innovative options like studying
groups of RDs with common underlying pathophysiology, or decentralized studies
leveraging on telemedicine, remote outcome evaluation, and data science, to
expedite the research yield and identify new therapeutic agents or re-purpose existing
therapies.

**Dysfunctional regulatory components**

On one hand, the generation of regulatory-compliant research results, and thus the
translation and uptake of academia-driven research, is often compromised by lack of
timely regulatory advice and interaction beforehand with regulators. On the other
hand, there is a need to engage and boost regulatory science to provide a robust,
more digital framework and accelerate implementation of novel technologies,
innovative trial design or the use of Real-World Evidence (RWE) in study design and
development.

**2.1.2. Scope**

To address the above challenges and enable accelerated translation of knowledge
into health interventions and other services, under this specific objective the
partnership will enable patient-need led relevant science by providing a RD research
support pipeline from basic research to clinical trial readiness. To better target
underserved RDs activities it will investigate mechanisms underlying disease and
disease progression, biomarkers and identification and validation of other tools to
promote prevention, inform development of treatments, diagnostics, and other
innovative healthcare solutions. Attention will be paid to Social Sciences and
Humanities research to better understand the impact of rare diseases and the
potential benefit of new interventions. Furthermore, the partnership will explore
research/diagnostic/therapeutic/data science approaches for multiple diseases with
common aetiology/pathway/other characteristics, taking account of their impact on
regulatory requirements and processes.

The integration across value chain will be addressed by combining research financed
and performed by both public and private stakeholders and involving patients. This
coupled with effective support services including state-of-the-art data infrastructure
(SO2) and research pipeline coordination will directly boost innovation in rare disease
diagnostics, therapeutics and other interventions such as prevention. The partnership
will aim to unite and strengthen the research ecosystem by creating infrastructures
that address connectivity and maximize various public and private resources to
support all steps of R&D, from discovery to late development, to post-marketing
obligations and backtranslation. Thereby, the partnership will increase reproducibility
of results and accelerating discovery, translational research and development.
Investment in outcome-oriented research projects, actively monitored and steered towards translational opportunities will ensure their outputs meet regulatory requirements and patients' needs thereby reducing failure rates of therapeutic developments. The Partnership will aim to support processes from preclinical to late development considering regulatory requirements. It will support development, regulatory acceptance, upscaling and deployment of innovative clinical trial methodologies (pooled design and analysis methods, AI, use of different sources of evidence, including RWE, data necessary to inform reimbursement decisions) for small and very small populations. Attention will be paid to demonstrate the value of new methodologies to standardize and benchmark them against existing regulatory and HTA evaluation and approval processes to help adapting them to rare disease specificity and engage regulatory acceptance.

Activities under this specific objective will be enabled by and will inform those of Specific Objective 2 (Data). Deployment of new methodologies in research, regulatory and HTA practice and health practice will rely on supportive activities under Specific Objective 4 (Capacity building). The integration of public and private resources into one research support pipeline will contribute to the strategy of Specific Objective 5 (Integrated multinational and multi-stakeholder R&I ecosystem for RDs).

### 2.1.3. Potential Outputs

- RD funding programme based on long-term ([amount to be defined] years) funding commitment and robust prioritization strategy.
- At least [amount to be defined] M€ invested in RD research focused on underserved rare diseases, including on the impact of RD on patients, families and society.
- [amount to be defined] M€ invested in projects using secondary use of clinical data and reuse of research data for RD prevention, earlier diagnosis, treatment, and mitigating impact on the life of people living with a rare disease.
- All funded projects accompanied by sustainable and integrative support services to accelerate the development-ready research and to guarantee generation of exploitable output.
- Functional RD research funding accelerator hub\(^7\) ensuring smooth transition and support all along value chain to expedite research results into products. Fully integrated and mutually synergistic non-clinical & clinical trial readiness RD research pipeline (including Clinical Research Network).
- The capacity of relevant clinical expertise coupled to methodological excellence exploited in coordination with regulators/HTA, to support evidence-based research accelerating the entry into market for the patient benefit.

\(^7\) The acceleration hub aims at promoting innovation, encourage collaboration, and support the translation of scientific discoveries into real-world applications that benefit society. As a collaborative and interdisciplinary service, it brings together researchers, entrepreneurs, investors, and other stakeholders to accelerate the development and commercialization of scientific and medical innovations. It offers a range of resources and services, such as funding, mentorship, access to specialized equipment, training, networking opportunities, and regulatory guidance, that help researchers and entrepreneurs move their ideas from the laboratory to the market more quickly and efficiently. Within the European RD Partnership, the acceleration hub will have a large scope including, but not limited to, biotechnology, drug development, medical devices and digital health, and will leverage on its public-private collaborations.
2.1.4. Specific Outcomes

- Research initiated in [amount to be defined] % of underserved rare diseases.
- Higher number of successful basic research projects transitioning to preclinical development.
- Increased number of academic projects transitioning to industrial development in the EU.
- Public Early-stage investment coordinated with later stage investment by private sector and philanthropy.
- Better and faster integration of novel technologies and methodologies along the RD healthcare pathway with a focus on specific subareas such as diagnosis, devices, trial readiness and integrated care.
- Increase in number of RD cases with a diagnosis.
- Increased integration of RD research and care.
- Increased number of investigational medicinal products implemented into clinical research and developed in Europe.

2.2. Specific Objective 2: Healthcare and research data are accessible, and used, for scientific and regulatory evaluation and healthcare delivery

2.2.1. Challenge

Projects and initiatives such as the EJP RD, JRC, ERICA, ERNs, RD-Connect, Darwin, C-Path, and Solve-RD, together with ELIXIR, 1+MG, BBMRI-ERIC, EOSC, and EHDS are gradually providing the foundations of a powerful, standards-based European RD data ecosystem. Herein, the RD community embraced the FAIR principles [Wilkinson et al.] to optimize how data can be used to reach tangible results. Nevertheless, the full potential of healthcare and research data for research, innovation, regulatory purposes, and healthcare delivery in the RD domain remains untapped to significant extent. There are major challenges regarding the awareness and integration of the accessible resources and the skills to fully exploit the data ecosystem. Challenges include planning studies that use data from multiple sources, analysing and interpreting data from such studies (e.g., by explainable AI and interdisciplinary collaboration), and translating insights from data research into actionable results e.g., treatments for individuals, clinical guidelines, development of drugs and devices, increased technology readiness, and improved HTA and reimbursement decisions. Increasing the capability of data producers in applying standards for accessibility, quality and interoperability of data is still a challenge. Full exploitation of data for the global objectives depends on widespread adoption of these standards.

2.2.2. Scope

The partnership will aim at strengthening selected ongoing and new actions to harness opportunities that well-managed healthcare and research data present for rare diseases. Opportunities include qualifying data pertinent to innovation for regulatory purposes, optimizing clinical trial readiness within the EU Clinical Research Network, RD
diagnosis in EU wide initiatives (e.g., EU-wide undiagnosed program), understanding
RD impact and burden, and exploiting patient-centred outcomes.

The European RD Partnership will support the generation, pooling, integration and
sharing of high-quality and interoperable RD data in an expanding ecosystem of
distributed FAIR data sources, building on existing infrastructures encompassing the
European Platform on Rare Disease Registration, the EJP RD Virtual Platform network,
RD-Connect, and services not specific for RD (e.g., BBMRI-ERIC and ELIXIR). It promotes
advanced data analysis and data interpretation methods and approaches that
exploit this ecosystem. Approaches are as federated as possible and as centralised
as needed to enable robust and flexible data use scenarios that promote
collaboration among European countries and stakeholders, facilitate research,
innovation and regulatory qualification of data, as well as better translate into tangible
healthcare benefits for RD patients, contributing thus to the SO5.

The partnership will also support the development of data-driven computational tools,
statistical and artificial intelligence methods, as well as digital solutions to understand
the diseases progression, to solve undiagnosed RD cases and implement new clinical
studies/trials designs for small populations, this will be enabled by and will inform the
activities of the Specific Objective 1. The involvement of RD patients and clinicians is
essential to ensure that advanced computational data access, analysis and
modelling tools are being developed, considering user needs, utility and sustained
exploitation early on, with patient’s health outcome improvement being the key
driver. This will rely on supportive activities of SO3 and SO4 for patients’ empowerment
and capacity building of RD stakeholders.

Advancing RD data standards, harmonising data access services and deploying high
performance data analysis capacities will be promoted within the partnership in
coordination with the activities of the SO5, through the collaboration with existing
national, EU and international data initiatives and infrastructures.

2.2.3. Potential Outputs

- Exploitation of FAIR repositories of clinical and omics RD data on a European scale,
extending to Patient Reported Outcome Measures (PROMs), longitudinal real-
world observations, streaming data, and data from wearables.

- An EU-wide undiagnosed programme based on the effective detection of
undiagnosed RD patients in national health systems and on an infrastructure of FAIR
reference data (phenomics, genomics, multi-omics, etc.).

- A comprehensive data infrastructure based on FAIR principles, existing resources,
data protection regulation, and quality standards including validated Patient
Centred Outcome Measures (PCOMs) to support patient-centred research, as well
as regulatory and HTA decision making.

- Promoting the regulatory qualification of RD data with the goal of accelerating the
development and access of therapies, and measurements or methods that aid
therapy development across rare diseases.

- A FAIR data-based framework exploiting patient-driven health and socioeconomic
studies to inform policy decisions.

- Widespread use of data-driven computational tools and models, artificial
intelligence methods and digital solutions that exploit the FAIR data ecosystem to
advance trial readiness, to solve undiagnosed RD cases, to understand disease
progression, develop and validate clinically meaningful trial outcomes, and
implement innovative clinical study/trial designs for small populations.
• Collaboratively developed knowledge platform for open access, dissemination and sharing of scientific knowledge, including negative results and data.

• Data standards for making new types of data elements FAIR, including real world observations and evidence, patient reported outcomes, and data required to satisfy regulatory requirements.

• Demonstrations of the value of a critical mass of FAIR data for secondary use of clinical data and reuse of research data for RD prevention, earlier diagnosis, treatment, and mitigating impact on the life of people living with a rare disease.

2.2.4. Specific Outcomes

• Improved RD diagnosis (higher diagnostic yield, earlier diagnosis) through FAIR data use.

• Support for symptomatic patients without a satisfactory diagnosis.

• Improved trial readiness and therapeutic options through FAIR data use.

• Accelerated development of therapies across rare diseases, facilitated through regulatory-grade data that are FAIR for analytics supporting RD characterization.

• Increased accuracy of diagnosis and individualised treatments from clinical decision support using advanced data driven methodologies/analytics.

• Reduced time-to-use of therapeutic solutions in a clinical context by advanced data driven methodologies/analytics.

• Increased availability and usability of RD innovation.

• Demonstrated added value of digital health tools for RD.

• Researchers, patients and clinicians are increasingly re-using and sharing RD data to implement multinational research for delivering new concepts in RD pathophysiology, new diagnostics, novel drug targets, biomarkers and new disruptive approaches for clinical research.

2.3. Specific Objective 3: All activities empower, as equal partners, people living with rare disease

2.3.1. Challenge

Research on RD should create value first and foremost for patients. People living with a RD are often the most motivated stakeholders to make progress on their disease given the number of patients living with the disease is low and that knowledge, expertise and funding are scarce. At the same time, patients and carers are often a significant source of expertise related to individual rare diseases. Only by harnessing patient expertise, together with clinical and research expertise, can we address the challenges posed by RD.

Although patient engagement is recognised as a cornerstone of the RD ecosystem, obstacles remain to genuine and significant involvement of patients in research. More specific challenges arise for the ‘undiagnosed’ and ultra-rare diseases, where collaboration across sectors and geographic borders is indispensable but where research activity lacks scale and visibility among patients who would like to participate. Resources are not targeted to research on RD with the highest unmet
needs and access for patients to interrogate limited existing research sources is not eased. Patient involvement is not systematic and/or capitalised on to generate data that support decisions making by regulators or payers. Furthermore, there is currently insufficient patient participation at all levels of research to enable productive and sustainable partnerships between researchers and patients. This includes incentives (funding, regulatory) to enable equitable inclusion of Patients Living With a Rare disease (PLWRD) and/or representatives from the earliest point of research or participation of patients/patient organisations as co-designers of research. Coordinated cooperation in the development of the RD disease specific patient-centred outcome measures (PCOMs/PROMs), consideration of patient preferences, and co-development of Real-World Evidence (RWE) must also be stimulated. Thus, an organized framework for patient involvement in research, building upon what has been initiated by the EJP RD, is required to systematically support patient-centred research and deliver new innovations.

2.3.2. Scope

The European RD Partnership will provide an inclusive pathway and adequate resources to empower PLWRD and/or representatives as equal partners. PLWRD will be involved at all levels of governance and execution of the European RD Partnership, with training or induction as necessary. A structured, flexible and coherent framework for patient engagement in research will be developed which will be adaptable at national levels and will promote best practices, re-using and extending existing resources (such as PARADIGM, EJP RD PENREP®, etc.). Patients and/or representatives will be active and equal partners in planning and prioritising research activities, engaging in projects and facilitating patient engagement across all research activities, encompassing implementation, monitoring and dissemination of projects’ results. Training for patients/patient representatives will be provided on a continuous basis to ensure and accelerate their informed engagement at all levels. Patients will also have a role in identifying training needs for researchers and clinicians working with people with rare diseases, so that training on patient involvement in research will be provided to funded projects. Novel and more inclusive funding models will be developed to ensure sustainable patients’ involvement in research projects and to ensure that availability of funding is not a barrier to patient participation at a national/regional level. PLWRD will be engaged in decision-making on the allocation of funding to research projects (including evaluation and monitoring).

The European RD Partnership also aims to reduce inequities between different types of RD by targeting underserved RDs through meaningful empowerment, engagement, and leadership of patients or their advocates, building new or expanded networks and supporting dedicated research. In developing this inclusive pathway, the European RD Partnership will take advantage of the existing infrastructures like Patient Advocacy Organisations (agnostic or RD specific), RD Patient National Alliances, the ERNs and their European Patient Advocacy Groups (ePAGs), charities, etc.

---

8 The EJP RD PENREP, Patient Engagement in Biomedical Research Project, working group is composed of patients’ representatives and research funders who aims to encourage fruitful, sustainable and enduring partnerships between scientists and patient organisations, co-leading the way for systematic patient-centered research.
2.3.3. Potential Outputs

- Patient-informed decision making, on which unmet needs to investigate and prioritize in research is made.
- Patient representation in all governance structures within the European RD Partnership.
- Patients/patients' representatives involved in all research applications and on steering/governing committees of all funded RD studies.
- Effective patient partnerships enabled through dedicated funding of patient organisations contributing to research projects.
- Agreed mechanisms to feedback research results in a consistent and systematic way to relevant patient groups.
- Awareness and adequate signposting of the infrastructures and resources available to support and guide patients in the RD Research landscape.
- Patient empowerment through capacity building and training activities resulting in proactive patient partnerships in research.
- Increased knowledge within PLWRD to further understanding of rare diseases.
- The training on patient involvement in research is coupled to every funded research project.
- PCOMs/PROMs co-developed by PLWRD and applied across all relevant funded research and all 24 ERNs.
- Guidelines developed to support equitable patient inclusion to inform researchers, regulators and funders at the national and European levels.

2.3.4. Specific Outcomes

- Increased participation of patients/patient organisations as co-designers of research Innovative and disruptive approaches in funding and developing patient-centred research benefitting the whole health research ecosystem.
- Patient voices are considered when deciding about research priorities and strategies.
- A greater sense of shared ownership of the research process/outcomes.
- Trusted relationships to access resources, expertise and the support required to translate research into positive health impact.
- A better understanding of the real needs and preferences of patients informing research questions and driving new design interventions.
- Healthcare solutions assessed according to criteria that matter to patients and public contributing to achieving people-centred healthcare.
- Building legal requirements for equitable inclusion in all levels of engagement in research.
2.4. Specific Objective 4: Increased capacity and skills of RD stakeholders to optimise research to healthcare continuum

2.4.1. Challenge

The capacity building element is often underestimated when considering the long-term strategy for building strong rare diseases ecosystem. Despite several efforts deployed by the EJP RD, ERNs or EURORDIS to provide a wide range of knowledge sharing, training and educational activities for RD research stakeholders, there is still an unmet need for an integrated concept combining systematic and comprehensive knowledge transmission with targeted acquisition of specialized skills in order to increase the EU’s RD research capacity in an efficient and sustainable manner.

Both raising new generations of RD researchers/clinical specialists/patient experts and continuous acquirement of new competences by RD stakeholders are main challenges augmented by fragmentation and lack of sustainability of existing training and education programmes. This is even more evident at national level where specialised curricula are incomplete or simply do not exist and the sharing of available knowledge is slowed down due to the language barriers. Furthermore, efficient capacity building is hampered by the absence of a central knowledge hub allowing on the visibility of existing expertise and contributing to better alignment of efforts deployed under different initiatives (including the bottom-up funding programmes of the European Commission that generate important volume of RD-related projects).

2.4.2. Scope

The partnership will incorporate capacity building activities as integral part of the rare disease research pipeline. Alignment with the knowledge generating actions of the initiatives (ERNs, C4C, STARS, etc.) will be sought. This will enable, on one hand, upgrading of scientific, technology (including FAIR approaches) but also regulatory knowledge of stakeholders participating in research projects financed through competitive calls but also those performing “in house” research activities as part of the Clinical Research Network of the European RD Partnership. On the other hand, new generations of RD researchers will be equipped with state-of-the-art competences.

Young researchers will be given the opportunity to train during interdisciplinary liaison programmes and secondment coupling clinical and non-clinical activities.

To unlock the access to RD top-level education to all, the partnership will develop an accredited, comprehensive online education programme taking stock of highly performing pre-existing modules complemented by novel training units.

The model of “train the trainer” and innovative language AI technologies will be used to expand and deliver capacity building programmes in all countries participating in the partnership.

Finally, the partnership will provide a central platform for knowledge sharing by gathering and enabling access to relevant expertise (comprehensive catalogue & helpdesk) and ensuring connection with all existing RD projects and initiatives. This will provide novel opportunities for collaboration, improve the visibility of RD stakeholders and optimise the use of resources by enhancing the performance of previously disconnected activities.

2.4.3. Potential Outputs

- All researchers in funded projects have access to suitable training courses/certification.
• Interdisciplinary mobility programmes for early career researchers linked to and optimally serving the needs of consortia supported by the partnership.

• European Master graduation programme enabling training of new generations of RD researchers.

• RD stakeholders empowered and mastering methodologies required to generate and use good-quality data according to European standards.

• Increased participation of researchers from under-represented countries in education/training programmes.

• Train-the-trainer programmes enabling capacity building at national level, including under-represented countries.

• Central knowledge hub enabling mapping and access to existing expertise, resulting in improved knowledge transfer and forging new collaborations.

2.4.4. Specific Outcomes

• A new generation of researchers trained in transdisciplinary, patient-centric RD research interconnected with clinical care.

• The EU equity among countries for RD capacity building is increased.

• National/regional training and education programmes are aligned with European standards.

• Increased awareness of RD stakeholders of the needs of translational and clinical RD research.

• The EU RD capacity building is increased.

2.5. Specific Objective 5: Integrated multinational and multi-stakeholder Research & Innovation ecosystem for RD

2.5.1. Challenge

In the field of rare disease research (e.g., RD diagnostics, therapeutic development, trial readiness networks) cross-national, cross-disciplinary, cross-sectoral and multi-stakeholder collaboration lays the ground for scientific and technological progress that translate in innovative and relevant research results and improvements of care. However, the opportunities for integrating the different national, European and international collaboration in the diverse areas along the healthcare pathway have not been fully harnessed yet. The challenge can be divided around four main axes:

(1) Multi-stakeholder collaborations that still suffer from insufficient number of effective public-public and public-private collaborations that are translated towards application, due to lack of trust to open every tool to the most effective type of collaboration, backed by lack of awareness of needs of other actors in R&I value chain and persisting gaps in the funding pipeline. This includes also lack of a structured and continuous dialogue among regulatory agencies, payers and developers on common challenges.

(2) National-EU-international alignment, especially operative integration of national capacities as part of a multinational ecosystem. This involves lack of suitable governance models and federated solutions enabling data access/visiting across different data sources in different countries or of sustainable models for the collection of RWE and data on burden of disease (including societal costs), closely linked to the
Specific Objective 2; but also insufficiently coordinated policies and R&I funding for RD in multiple countries.

(3) Collaboration between existing projects/programmes or initiatives that is subject to fragmentation and duplication of efforts which translates into lack of sustainability and innovation drop rate in EU.

(4) Participation and visibility of under-represented countries.

2.5.2. Scope

To address the above-mentioned challenges the Partnership will break the silos between communities by consolidating the already existing strong community, currently mostly consisting of public sector researchers, research infrastructures as well as RD patients and representatives, and stepping-up the integration of underrepresented perspectives, namely the industry, regulatory bodies and payers.

This will be reflected by relevant governance and advisory structures but also overall Partnership organisation to ensure coherence and maximise impact of all actions.

Contribution to RD Moonshot objectives will be essential. Furthermore, through dedicated onboarding mechanisms, the European RD Partnership will gradually bring in additional players to attract and increase the critical mass of resources, know how, talents and excellence, but also to erase white spots on the RD research map and offer equal opportunities to patients across Europe and beyond. The integration of the Scientific Secretariat of IRDiRC will be key to provide strong links to international collaborators as well as a joint management of research and innovation strategy. This will be particularly relevant to drive and support the participation of members from the US National Institutes of Health who are also members of the IRDiRC Consortium Assembly and participate in its activities. These interactions will stimulate the European added value in the field of international collaboration to advance faster toward the vision and goals defined by IRDiRC.

The proposed European RD Partnership will also catalyse the transfer of good practices to the national and regional level, including leveraging the power of national/European resources, making them discoverable and actionable for international RD research. In this regard, the role of National Mirror Groups will be extremely important to ensure meaningful collaboration with and between countries, since they will bring together the national representatives of the European RD Partnership and other relevant RD stakeholders.

By default, the Partnership will build on previous and currently operating actions in the RD field such as EJP RD, Solve-RD, ERICA, 1+MG, EHDS or the forthcoming JA on ERNs to help leverage the existing capacities. It will also ensure close alignment and (when possible) joint activities with other Horizon Europe partnerships (e.g., IHI, EIT Health, Innovative SMEs, ERA4Health and Partnerships on Personalised Medicine and Healthcare Systems) as specified in the Synergies with other initiatives section.

2.5.3. Potential Outputs

- Structured and enabling environment for multistakeholder and multinational governance and consultation upstream (researchers, industry, patients, regulators), to define common and concerted objectives, considering the constraints of each and aligned with the needs of patients.

- RDP used as multistakeholder platform for dialogue to support technical questions, but also social challenges and policy debates linked to RD research (drug regulation, diagnostics, medical devices).
• By end of the Partnership all partner countries have an active National Mirror Group supporting alignment of goals, strategies and shared best practices.

• Efficient mechanisms to identify, onboard and deploy high value (national) resources, services and tools that are valuable to the RD community.

• Effective transcontinental collaboration through integration of IRDiRC recommendations, accessibility to European RD Partnership resources and shared research, clinical and development opportunities.

• Set-up complementarities and synergies with other relevant programmes and initiatives.

• Integrative solutions and research pipelines for RD subareas such as diagnosis or trial readiness that integrate and leverage the existing European and national RD research actions.

• Structural involvement of regulatory bodies (medicines, diagnostics, reimbursement agencies) in all actions involving research.

• Enable novel collaborations between funders, regulators, payers, and other sectors through provision of frameworks and models for multi-stakeholder collaboration.

• Improved trial readiness of clinical research sites.

2.5.4. Specific Outcomes

• RD patient benefits from research results that were enabled through the multi-national and multi-stakeholder Research & Innovation ecosystem for RD.

• National resources and capacities are supported, optimised and fully integrated in the overall RD ecosystem and their use maximised for the benefit of people living with rare diseases.

• Sustainable national RD research strategies, aligned with and benefiting from EU and international collaborations in all participating countries.

• Successful implementation of transcontinental collaboration.

• Improved coordination of EU initiatives and enhanced EU leadership in RD field.

3. Performance Indicators

Under development

These Performance indicators are designed to measure the outputs, the outcomes of the European Rare Diseases Partnership Objectives (General Objectives and Specific Objectives). This is work in progress; the final KPIs may be different from what is listed below.

General Objective 1 “DIAGNOSIS ESTABLISHED OR ENROLLMENT IN SYSTEMATIC RESEARCH IN AVERAGE WITHIN 6 MONTHS AFTER COMING TO MEDICAL ATTENTION”:

• Number of undiagnosed patients who receive a confirmed diagnosis or enrolled in systematic research within 6 months after first medical examination at secondary care level, facilitated by the partnership.
• Number of improvements on the time to diagnose patients seeking medical attention for an unknown condition.

• Number of improvements (efficiency, quality) in all steps underlying diagnosis, from gains in fundamental research (e.g., biomarkers) to the clinical journey of a patient.

• Number of countries having undiagnosed programmes/activities.

• Best practices developed within diagnosis-translational pipelines disseminated or adopted or implemented, by diagnostic centres.

**General Objective 2** “1000 NEW THERAPIES FOR RARE DISEASES APPROVED”:

• Number of new therapies approved for rare diseases per year.

• Number of clinical trials conducted for new therapies for rare diseases

• Number of partnerships between industry, academia, and government to develop new therapies for rare diseases

• Time to approval for new therapies for rare diseases

**General Objective 3** “BETTER UNDERSTANDING OF THE IMPACT OF RD ON PATIENTS, FAMILIES AND SOCIETY”:

• Number of publications and presentations on the impact of rare diseases in scientific conferences, policy briefings, and media outlets

• Number of research studies conducted on the impact of rare diseases on patients, families, and society

• Number of policy changes or initiatives at local, national, and international levels aimed at addressing the impact of rare diseases on patients, families, and society

• Number of collaborations between patient groups, academic researchers, industry, and government to address the impact of rare diseases

• Increase in funding for research on the impact of rare diseases on patients, families, and society

**Specific Objective 1** "Generation of knowledge and its translation into medical and holistic intervention”:

• Number of funded RD projects

• Number of transitions from one phase in the value chain to the next

• Number of collaborations between research institutions and healthcare providers

• Number of publications resulting from RD research projects supported by the Partnership

• Number of RD projects funded using secondary use of clinical data
• Number of collaborations between academic researchers, industry, and patient advocacy organizations to develop and implement medical and holistic interventions for RD
• Funding for RD research and development of medical and holistic interventions within the Partnership (per year)
• Number of research projects initiated within the Partnership in collaboration with patients / patient organisations
• Number of RD research projects supported by the Partnership (or a previous co-fund on Rare Diseases) resulting in drugs approved by EMA/FDA, patents and new companies
• Number of new RD cases with a diagnosis facilitated by the Partnership
• Number of businesses spinning off and/or direct benefiting from funded project results

Specific Objective 2 "Healthcare and research data are accessible, and used, for scientific and regulatory evaluation and healthcare delivery":
• Number of researchers, patients, and clinicians who are re-using and sharing rare disease data to implement multinational research, as evidenced by published research papers, patents, and collaboration agreements.
• Number of healthcare and research data sources that are made available for scientific and regulatory evaluation and healthcare delivery
• Number of cases where healthcare and research data use led to a clinically or biomedically relevant outcome (interventions, diagnosing an undiagnosed case, new biomarker, new candidate drug for repurposing)
• Number of validated Patient-Centred Outcome Measures (PCOMs) included in the comprehensive data infrastructure based on FAIR principles.
• Number of clinical trials that are initiated or have progressed due to improved trial readiness and therapeutic options through FAIR data use

Specific Objective 3 "All activities empower, as equal partners, people living with rare disease":
• Number of patients empowered, within the Partnership, through capacity-building and training activities related to research.
• Number of funded research projects that involve patients/patient organisations as co-designers.
• Percentage of research studies that have involved patient representatives in their governance and decision-making structures.
• Number of guidelines developed with patients or patient organisations (when they exist) to support equitable patient inclusion in research, and their adoption by relevant stakeholders.
• Adoption of patient-informed decision-making processes for prioritizing research questions and agendas.
• Number/percentage of research questions/interventions that have been informed by patient needs and preferences

• Percentage increase in the number of people living with rare diseases who are trained to become advocates and participate in advocacy and awareness-raising campaigns.

Specific Objective 4 "Increased capacity and skills of RD stakeholders to optimise research to healthcare continuum":

• Number of national/regional training and education programs aligned with RDP

• Number of RD stakeholders who participate in training programs to enhance their research skills and capacity

• Number of train-the-trainer programmes implemented for capacity building at national level, including under-represented countries

• Number of researchers from under-represented countries who have participated in education/training programmes

• Number of transdisciplinary research training programs developed and implemented at the European level.

Specific Objective 5 "Integrated multinational and multi-stakeholder Research & Innovation ecosystem for RD":

• Number of countries with sustainable national RD research strategies aligned with EU and international collaborations.

• Number of active National Mirror Groups by the end of the Partnership.

• Increase in the number of funding programs and initiatives dedicated to RD research and innovation, at both national and European levels. (indicating improved political commitment and public awareness of the RD challenge)

• Number of complementarities and synergies established with other relevant programmes and initiatives.

• Increase in the number of clinical trials conducted in multiple countries. (indicating improved harmonization of regulatory frameworks and ethical standards, and increased cross-border collaboration among researchers and institutions)

4. Conclusions

Under development
### 5. Annexes

#### 5.1. Annex 1 - European Partnerships, EU Missions, EU Programmes, Projects and Organisations of potential relevance

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Objectives</th>
<th>Pre-identified synergies (non-exhaustive)</th>
</tr>
</thead>
</table>
| **ERA4Health**  
*EU Partnership _ Health Cluster* | The partnership aims to establish and implement a strategic research agenda and joint funding strategy between major European public funders to advance health research and develop innovation. As well as to develop new approaches that overcome known challenges in multinational clinical research. This will be achieved in close collaboration with ongoing initiatives to support the conduct of multinational non-commercial studies. This would lead to establishing appropriate mechanism(s) for identifying topics and funding sources, and for launching (joint) calls for large, multinational Investigator Initiated Clinical Studies on various health interventions addressing important public health needs. | • The model for establishment and financing of multinational clinical trials.  
• Possible joint funding activities on transversal topics |
| **Innovative Health Initiative (IHI)**  
*EU Partnership _ Health Cluster* | A collaborative platform bringing the several industry sectors (pharmaceuticals including vaccines, diagnostics, medical devices, imaging and digital sectors) together with academic partners for precompetitive research and innovation in areas of unmet public health need, to accelerate the development and uptake of people-centred health care innovations. Since some projects under the Innovative Medicines Initiative (IMI), predecessor of IHI, are still running / will deliver a legacy useful for the RD Partnership, synergies will be sought with them too. | • Joint activity on Accelerator Hub  
• Alignment with IHI projects related to RD or relevant platforms (e.g., clinical trials, use of data, regulatory aspects) |
<table>
<thead>
<tr>
<th>Initiative</th>
<th>Objectives</th>
<th>Pre-identified synergies (non-exhaustive)</th>
</tr>
</thead>
</table>
| **Personalised Medicine** [EU Partnership _ Health Cluster] | To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine and enhance the collaboration with non-EU countries. | • Data infrastructure  
• Possible joint calls  
• Personalised treatment approaches |
| **Transforming Health and Care Systems (THCS)** [EU Partnership _ Health Cluster] | Improving health and care models in an ageing, data-driven and digital society, shifting to holistic health promotion and person-centred care approaches through health policy and health systems research (including guidance on how to transform health systems; developing new solutions for health and care; strengthening innovation and its successful transfer to health care systems). | • Innovative solutions and their integration in healthcare systems  
• Models for research to healthcare pathway |
<p>| <strong>Artificial Intelligence, data and robotics</strong> [EU Partnership _ Digital, Industry and Space Cluster Cluster] | The partnership on AI will help structuring the European AI community, develop a strategic research agenda and federate efforts around a topic that holds great potential to benefit our society and economy. | • Optimisation of data use through AI technologies (e.g., diagnostics) |
| <strong>High Performance Computing</strong> [EU Partnership _ Digital, Industry and Space Cluster Cluster] | The EuroHPC will establish an integrated world-class supercomputing and data infrastructure and support a highly competitive and innovative HPC and Big Data ecosystem. | • Optimising RD data infrastructures |</p>
<table>
<thead>
<tr>
<th>Initiative</th>
<th>Objectives</th>
<th>Pre-identified synergies (non-exhaustive)</th>
</tr>
</thead>
</table>
| **Innovative SMEs**<br>[EU Partnership _ Other Partnerships [across other themes]] | The initiative aims to support the transnational market-oriented research projects initiated and driven by innovative SMEs. Innovative SMEs shall take the lead and exploit commercially the project results, thus improving their competitive position. Research organisations, universities, other SMEs, large companies and other actors of the innovation chain can also participate. | • Joint funding models  
• Public-private collaboration (Proof of Concepts for RDs)  
• Optimisation of support for innovative SMEs in the space of RDs |
| **European Institute of Innovation & Technology Health (EIT Health)**<br>[EU Partnership _ Other Partnerships [across other themes]] | Backed by the European Union EIT Health will be delivering solutions to enable European citizens to live longer, healthier lives by promoting innovation, improving health care for citizens and strengthen the health economy in Europe. | • Joint training activities  
• Accelerator hub |
| **European Open Science Cloud (EOSC)**<br>[EU Partnership _ Other Partnerships [across other themes]] | The co-programmed partnership aims to improve the storing, sharing and especially the combining and reusing of research data across borders and scientific disciplines. The Partnership brings together institutional, national and European initiatives and engages all relevant stakeholders to co-design and deploy a European Research Data Commons where data are Findable, Accessible, Interoperable, Reusable (FAIR). | • Optimisation and integration of RD data infrastructure  
• Expansion of data sources for the benefit of RDs |
| **EU Mission: Cancer** | New initiative rooted in Horizon Europe’s research and innovation programme to improve the lives of more than 3 million people by 2030 through prevention, cures, and for those affected by cancer and their families, to live longer and better with 4 key objectives: understand cancer and its risk factors; Prevent what is preventable; Optimise diagnostics and treatments; Support the quality of life of people. | • Innovative and holistic research to healthcare pathway models  
• Possible joint activities (including funding) fostering rare cancers |
<table>
<thead>
<tr>
<th>Initiative</th>
<th>Objectives</th>
<th>Pre-identified synergies (non-exhaustive)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Digital Europe Programme</strong></td>
<td>A new EU funding programme focused on bringing digital technology to businesses, citizens and public administrations.</td>
<td>• Digital tools for the benefit of RD community (diagnosis, RWE, PCOMs, etc.)</td>
</tr>
<tr>
<td>[EU Programme]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>European Innovation Council – (EIC)</strong></td>
<td>It aims to identify and support breakthrough technologies and game changing innovations to create new markets and scale up internationally.</td>
<td>• Accelerator hub</td>
</tr>
<tr>
<td>[EU Programme]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **EU4Health**                 | EU programme of €5.3 billion complementing EU countries’ policies with four main goals: 1) to improve and foster health in the EU, 2) to tackle cross-border health threats, 3) to improve medicinal products, medical devices, and crisis-relevant products, 4) to strengthen health systems, their resilience and resource efficiency. Under these 4 general goals, 10 specific objectives are pursued and several of them are relevant for the RD Partnership for example:  
  • Action grants for developing a pilot project for an EU infrastructure ecosystem for the secondary use of health data for research, policy-making and regulatory purposes.  
  • Action grants supporting training activities, implementation, and best practices.  
  • Action grants to organise and collect data to understand the safety, quality and efficacy of therapies applied in the field of assisted reproduction and based on haematopoietic stem cells. | • Maximized alignment of funding and activities supporting healthcare (especially ERNs)                  |
<p>| [EU Programme]                |                                                                                                                                                                                                          |                                                                                                           |</p>
<table>
<thead>
<tr>
<th>Initiative</th>
<th>Objectives</th>
<th>Pre-identified synergies (non-exhaustive)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>European Regional Development Fund (ERDF)</strong> [EU Programme]</td>
<td>It aims to strengthen economic, social and territorial cohesion in the European Union by correcting imbalances between its regions. It will enable investments in a smarter, greener, more connected and more social Europe that is closer to its citizens.</td>
<td>• Use of structural funds to support research funding and Clinical Research Network (including facilities/infrastructure)</td>
</tr>
<tr>
<td><strong>European Social Fund Plus (ESF+)</strong> [EU Programme]</td>
<td>The main EU instrument for investing in people and supporting the implementation of the European Pillar of Social Rights. With a budget of almost EUR 99.3 billion for the period 2021-2027, the ESF+ will continue to provide an important contribution to the EU’s employment, social, education and skills policies, including structural reforms in these areas.</td>
<td>• Use of structural funds to support research funding and Clinical Research Network (including facilities/infrastructure)</td>
</tr>
<tr>
<td><strong>Horizon Europe</strong> [EU Programme]</td>
<td>The EU’s key funding programme for research and innovation with a budget of €95.5 billion. The programme facilitates collaboration and strengthens the impact of research and innovation in developing, supporting and implementing EU policies while tackling global challenges. It supports creating and better dispersing of excellent knowledge and technologies.</td>
<td>• RD knowledge hub (sharing of competences and outputs generated by HE funded projects) • Complementary funding</td>
</tr>
<tr>
<td><strong>InvestEU</strong> [EU Programme]</td>
<td>It will provide the EU with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It will also help mobilise private investments for the EU’s policy priorities, such as the European Green Deal and the digital transition. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub, and the InvestEU Portal. The InvestEU Fund will be implemented through financial partners who will invest in projects using the EU budget guarantee of €26.2 billion. The entire budgetary guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.</td>
<td>• RD knowledge hub (sharing of competences and outputs generated by HE funded projects) • Complementary funding • Accelerator hub</td>
</tr>
<tr>
<td>Initiative</td>
<td>Objectives</td>
<td>Pre-identified synergies (non-exhaustive)</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>-----------------------------------------</td>
</tr>
<tr>
<td><strong>Accelerating research &amp; development for advanced therapies (ARDAT)</strong> (IMI project 2020-2025)</td>
<td>IMI project which aims at delivering the knowledge, tools and standards needed to speed up the development of Advanced Therapy Medicinal Products (ATMPs).</td>
<td>• Outputs to be integrated into the CRN research strategies</td>
</tr>
<tr>
<td><strong>conect4children - Collaborative network for European clinical trials for children (c4c)</strong> (IMI project 2018-2024 that will be replaced by a sustainable legal entity from 2023)</td>
<td>Large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population. It is builds capacity for the implementation of multinational paediatric clinical trials whilst ensuring the needs of babies, children, young people and their families are met. It is committed to meeting the needs of paediatric patients thanks to a novel collaboration between the academic and the private sectors. c4c endeavours to provide a sustainable, integrated platform for the efficient and swift delivery of high-quality clinical trials in children and young people across all conditions and phases of the drug development process.</td>
<td>• Contribution to CRN</td>
</tr>
<tr>
<td>Initiative</td>
<td>Objectives</td>
<td>Pre-identified synergies (non-exhaustive)</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®)</strong> [Project or Organisation]</td>
<td>An FDA-funded initiative that provides a centralized and standardized infrastructure to support and accelerate rare disease characterization, with the goal of accelerating therapy development across rare diseases. RDCA-DAP promotes the sharing of existing patient-level data and encourages the standardization of new data collection. By integrating such data in a regulatory-grade format suitable for analytics, RDCA-DAP accelerates the understanding of disease progression (including sources of variability to optimize the characterization of subpopulations), clinical outcome measures and biomarkers, and facilitates the development of mathematical models of disease and innovative clinical trial designs.</td>
<td>• Alignment/contribution to RD data infrastructure</td>
</tr>
<tr>
<td><strong>Data Analysis and Real World Interrogation Network (DARWIN EU)</strong> [Project or Organisation]</td>
<td>EMA coordination centre to provide timely and reliable evidence on the use, safety and effectiveness of medicines for human use, from real world health care databases across the EU</td>
<td>• Optimisation of RD data infrastructure, especially generation and use of RWE</td>
</tr>
<tr>
<td><strong>European Genomic Data Infrastructure</strong> [Project or Organisation]</td>
<td>The <strong>Genomic Data Infrastructure (GDI)</strong> project is enabling access to genomic and related phenotypic and clinical data across Europe. It is doing this by establishing a federated, sustainable and secure infrastructure to access the data. It builds on the outputs of the <strong>Beyond 1 Million Genomes (B1MG)</strong> project and is realising the ambition of the <strong>1+Million Genomes (1+MG) initiative.</strong></td>
<td>• Alignment/integration with RD data infrastructure • Re-use of genomic data for diagnosis</td>
</tr>
<tr>
<td>Initiative</td>
<td>Objectives</td>
<td>Pre-identified synergies (non-exhaustive)</td>
</tr>
<tr>
<td>------------</td>
<td>------------</td>
<td>----------------------------------------</td>
</tr>
<tr>
<td><strong>European Health Data &amp; Evidence Network (EHDEN)</strong></td>
<td>IMI project that aims to build a large-scale federated network of data sources standardised to a Common Data Model.</td>
<td>• Optimisation of RD data infrastructure</td>
</tr>
<tr>
<td>• European Health Data Space (EHDS)</td>
<td>• Initiative by the EC to promote better exchange and access to different types of health data, to support health care delivery, health research and health policy making purposes.</td>
<td>• Alignment and integration of RD data infrastructure as part of the EHDS</td>
</tr>
<tr>
<td>• European Platform on Rare Disease Registration (EU RD Platform)</td>
<td>• To cope with the fragmentation of RD patients' data contained in hundreds of registries across Europe. • To act as a knowledge generation centre benefiting healthcare providers including European Reference Networks, researchers, patients, and policy makers in the common effort to improve diagnosis and treatment for patients living with a rare disease.</td>
<td>• Alignment/ integration with RD data infrastructure • Optimisation of the ERN registries</td>
</tr>
<tr>
<td>• ERICA (Coordination and Support Action under Horizon Europe, 2021-2025)</td>
<td>• Builds on the strength of the individual ERNs and create a platform that integrates all ERNs research and innovation capacity.</td>
<td>• Strategic alignment to optimise ERNs research activities</td>
</tr>
<tr>
<td>Initiative</td>
<td>Type of initiative</td>
<td>Objectives</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>GenoMed4ALL</strong>&lt;br&gt;[Organisation]</td>
<td>Objectives</td>
<td>The European initiative to transform the response to Haematological Diseases by seizing the power of Artificial Intelligence, pooling genomic/ ‘-omics’ health data through a secure and trustworthy Federated Learning platform. This stakeholder-driven and self-governed initiative aims to support implementation of the FAIR data principles via Global and Open FAIR implementation networks.</td>
</tr>
<tr>
<td><strong>Global Alliance for Genomics and Health (GA4GH)</strong>&lt;br&gt;[Project or Organisation]</td>
<td>Objectives</td>
<td>The Global Alliance for Genomics and Health fosters common technical standards, seeking to enable responsible genomic data sharing within a human rights framework.</td>
</tr>
<tr>
<td><strong>Gaia-X</strong>&lt;br&gt;[Project or Organisation]</td>
<td>Objectives</td>
<td>Gaia-X represents the next generation of data infrastructure: an open, transparent and secure digital ecosystem, where data and services can be made available, collated and shared in an environment of trust.</td>
</tr>
<tr>
<td><strong>Orphanet Data for rare Diseases (OD4RD) – Direct Grant</strong>&lt;br&gt;[Organisation]</td>
<td>Objectives</td>
<td>Contribute to standardized RD data generation by the maintenance and implementation of ORPHAcodes in Health Care Providers hosting ERNs, RD codification best practices, assistance and tools optimising data for primary and secondary use</td>
</tr>
<tr>
<td><strong>Patient Focused Medicine Development (PFMD)</strong>&lt;br&gt;[Project or Organisation]</td>
<td>Objectives</td>
<td>Not-for-profit collaborative initiative benefiting patients and health stakeholders by designing a patient-centred health care system with patients and all stakeholders.</td>
</tr>
<tr>
<td>Initiative</td>
<td>Objectives</td>
<td>Pre-identified synergies (non-exhaustive)</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| **Rare Disease Moonshot**                                                 | A coalition of public and private partners joining forces to accelerate scientific discovery and drug development in rare and paediatric diseases for which currently there is no therapeutic option. By fostering greater collaboration and improving the sharing of data and knowledge, they aim to accelerate clinical development of new solutions for adults and children living with rare conditions by developing novel clinical trials designs, enhancing data infrastructures and trial networks and defining processes adapted to very small populations. | • Strategic alignment  
• Public-private partnerships                                                                                                  |
<p>| <strong>Screen4care: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies (IMI project, 2021-2026)</strong> | IMI project that aims at shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies                                                                                                                                                                                                                                      | • Integration of outputs into the diagnostic pathway models of CRN                                                                 |
| <strong>Together4RD</strong>                                                           | A multi-stakeholder alliance supporting ERNs to collaborate with stakeholders, particularly with the pharmaceutical industry, to pursue opportunities that will address unmet medical needs of people living with rare diseases, in areas such as basic to translational research, clinical trials for rare &amp; ultra-rare conditions, testing and accelerating innovative approaches to diagnosis, development and implementation of data/evidence generation initiatives. | • Strategic alignment for public-private collaboration with ERNs                                                                 |</p>
<table>
<thead>
<tr>
<th>Initiative</th>
<th>Objectives</th>
<th>Pre-identified synergies (non-exhaustive)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Towards the European Health Data Space - Joint Action (TEHDAS JA)</strong></td>
<td>TEHDAS JA, funded under the EU Health Programme, helps EU MS and the EC to develop and promote concepts for the secondary use of health data to benefit public health and health research and innovation in Europe. It aims at enabling European citizens, communities and companies to benefit from secure and seamless access to health data regardless of where it is stored.</td>
<td>• Use of outputs to improve RD data (use and reuse) models</td>
</tr>
<tr>
<td>[Project or Organisation]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>X-eHealth</strong> [Project or Organisation]</td>
<td>EU-funded project that aims at developing the basis for a workable, interoperable, secure and cross border Electronic Health Record exchange Format in order to lay the foundation for the advance of eHealth sector.</td>
<td>• Alignment with CRN activities</td>
</tr>
</tbody>
</table>
## 5.2. List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>Artificial Intelligence</td>
</tr>
<tr>
<td>c4c</td>
<td>connect 4 children</td>
</tr>
<tr>
<td>CRN</td>
<td>Clinical Research Network</td>
</tr>
<tr>
<td>EC</td>
<td>European Commission</td>
</tr>
<tr>
<td>EHDS</td>
<td>European Health Data Space</td>
</tr>
<tr>
<td>EIC</td>
<td>European Innovation Council</td>
</tr>
<tr>
<td>EIT</td>
<td>European Institute of Innovation &amp; Technology</td>
</tr>
<tr>
<td>EJP RD</td>
<td>European Joint Programme on Rare Diseases</td>
</tr>
<tr>
<td>EOSC</td>
<td>European Open Science Cloud</td>
</tr>
<tr>
<td>EC</td>
<td>European Open Science Cloud</td>
</tr>
<tr>
<td>ePAG</td>
<td>European Patient Advocacy Group</td>
</tr>
<tr>
<td>ERDF</td>
<td>European Regional Development Fund</td>
</tr>
<tr>
<td>ERICA</td>
<td>European Rare Disease Research Coordination and Support Action</td>
</tr>
<tr>
<td>ERN</td>
<td>European Reference Network</td>
</tr>
<tr>
<td>ESF+</td>
<td>European Social Fund Plus</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FAIR</td>
<td>Findable Accessible Interoperable Reusable</td>
</tr>
<tr>
<td>GO</td>
<td>General Objective</td>
</tr>
<tr>
<td>HTA</td>
<td>Health Technology Assessment</td>
</tr>
<tr>
<td>IHI</td>
<td>Innovative Health Initiative</td>
</tr>
<tr>
<td>IMI</td>
<td>Innovative Medicines Initiatives</td>
</tr>
<tr>
<td>IRDiRC</td>
<td>International Rare Diseases Research Consortium</td>
</tr>
<tr>
<td>JA</td>
<td>Joint Action</td>
</tr>
<tr>
<td>JRC</td>
<td>Joint Research Centre</td>
</tr>
<tr>
<td>JTC</td>
<td>Joint Transnational Call</td>
</tr>
<tr>
<td>MSCA</td>
<td>Marie Sklodowska-Curie Action</td>
</tr>
<tr>
<td>NMG</td>
<td>National Mirror Group</td>
</tr>
<tr>
<td>OO</td>
<td>Operational Objective</td>
</tr>
<tr>
<td>PCOM</td>
<td>Patient Centred Outcome Measure</td>
</tr>
<tr>
<td>PENREP</td>
<td>Patient Engagement in biomedical Research Project</td>
</tr>
<tr>
<td>PLWRD</td>
<td>Patient Living With a Rare Disease</td>
</tr>
<tr>
<td>PROM</td>
<td>Patient Reported Outcome Measure</td>
</tr>
<tr>
<td>PSIP</td>
<td>Partnership Specific Impact Pathway</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development</td>
</tr>
<tr>
<td>R&amp;I</td>
<td>Research &amp; Innovation</td>
</tr>
<tr>
<td>RDP</td>
<td>Rare Diseases Partnership</td>
</tr>
<tr>
<td>RD</td>
<td>Rare Diseases</td>
</tr>
<tr>
<td>RWE</td>
<td>Real-World Evidence</td>
</tr>
<tr>
<td>SDG</td>
<td>Sustainable Development Goal</td>
</tr>
<tr>
<td>SME</td>
<td>Small and Medium Enterprise</td>
</tr>
<tr>
<td>SO</td>
<td>Specific Objective</td>
</tr>
<tr>
<td>SRIA</td>
<td>Strategic Research and Innovation Agenda</td>
</tr>
<tr>
<td>THCS</td>
<td>Transforming Health and Care System</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>----</td>
<td>----------------</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
</tbody>
</table>